截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 260,295,700 | RMB | | 1 RMB | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 260,295,700 | RMB | | 1 RMB | | 260,295,700 | | 2. 股份分類 | 普通股 | 股份類別 ...

记者丨孙燕 编辑丨陶力 张伟贤 在全球经济格局深刻重构的当下，上海浦东正以一种开放包容的姿态，举起全球化的大旗。 不同于以往的企业"单兵"出海、产业链"集群"出海，浦东正在探索一条更深层次、更富韧性的 路径——中外企业协同出海。 作为改革开放的前沿阵地，浦东正以其独特的开放基因和产业生态，将中外企业打造成一艘 艘"联合舰队"。这不仅是中国企业"走出去"的升级版，也是外资企业在华战略的新蓝海。 一幅多元共融的中外企业协同出海画卷正在浦东徐徐展开：罗克韦尔自动化、丹纳赫等生产 性服务外企正以数字化与生态优势赋能中企扬帆远航。与此同时，中建八局则凭借强大的总 包能力"链"动外企共拓海外版图，西门子能源等巨头也通过技术标准与供应链整合引领中企 走向全球。这些双向互动、互利共赢的实践共同交织成中外企业深度融合、协同出海的时代 图景。 " 1 + 1 > 2 " 坐拥全国最密集的跨国公司地区总部和外资研发中心集群，浦东在推动中外企业合作出海方 面有天然优势：截至2025年9月，上海累计认定跨国公司地区总部1060家、外资研发中心631 家，稳居我国内地首位。其中，浦东新区集聚了500家跨国公司地区总部，占上海市近一半。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 260,295,700 | RMB | | 1 RMB | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 260,295,700 | RMB | | 1 RMB | | 260,295,700 | | 2. 股份分類 | 普通股 | 股份類別 ...

以下文章来源于健闻咨询 ，作者健闻咨询 健闻咨询 . 医疗行业跨界洞察 第一财经、健闻咨询与上海现代服务业联合会医疗服务专业委员会联合发起的《2026医健可持续创新案例 推荐榜》如约而至，于2026年1月15日开始接受企业报名。 《2026推荐榜》以"智创融合，赋能医健产业可持续发展"为年度主题，突出人工智能与医疗健康的深度融 合，寓意以技术革新推动医健产业可持续发展。本届《推荐榜》在此前"国际创新本土化"、"本土创新全球 化"、"ESG创新实践"三个类别子榜单基础上，特别增设"医健+AI创新"类别，以响应人工智能为医健行业 带来的变革。 《医健可持续创新案例推荐榜》项目由第一财经、健闻咨询和上海现代服务业联合会医疗服务专业委员会 共同发起，联合"医健可持续创新案例提名委员会"提名并评选产生推荐榜案例，旨在为医疗大健康行业提 供可持续创新案例的分享交流平台。 《2026医健可持续创新案例推荐榜》 案例征集类别 国际创新本土化 本土研发与知识产权沉淀; 合规体系与商业模式本地适配能力; 本土制造与供应链整合度; 组织与人才体系的本地化建设; 对中国医疗体系的系统性贡献。 本土创新全球化 产品创新力与国际标准适配 ...

承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 董事會召開日期 上海君實生物醫藥科技股份有限公司（「本公司」，及其附屬公司「本集團」）董事會 （「董事會」）茲通告謹定於2026年3月13日（星期五）舉行董事會會議，以考慮及通 過本集團截至2025年12月31日止的年度全年業績，及考慮派發末期股息（如有） 以及處理其他事項。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 中國，上海，2026年3月2日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 ...

（於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2026年3月2日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 （股份代號：1877） 董事會召開日期 上海君實生物醫藥科技股份有限公司（「本公司」，及其附屬公司「本集團」）董事會 （「董事會」）茲通告謹定於2026年3月13日（星期五）舉行董事會會議，以考慮及通 過本集團截至2025年12月31日止的年度全年業績，及考慮派發末期股息（如有） 以及處理其他事項。 ...

1. Report Industry Investment Rating - No industry investment rating is provided in the report. 2. Core Views of the Report - From February 24 to February 27, 2026, all major equity market indices rose, with the CSI 500 having the largest increase of 4.32%. Among the 31 Shenwan primary industries, 25 industries rose, with the top five gainers being steel, non-ferrous metals, chemicals, environmental protection, and coal; the top five decliners were media, commercial trade, food and beverages, non-bank finance, and banks [1][12]. - The CSRC issued the "Administrative Measures for the Supervision of Information Disclosure of Private Investment Funds", which takes effect on September 1, 2026. The Shanghai Stock Exchange and China Securities Index Co., Ltd. announced the adjustment of constituent stocks of key indices such as the STAR 50, to be implemented after the close on March 13, 2026 [2][31][33]. - In terms of fund performance, quantitative funds had the largest increase, with an average increase of 2.22% and a positive return ratio of 92.26%. Fixed - income + funds rose 0.30% on average, with a positive return ratio of 73.12%. Pure - bond funds rose 0.01% on average, with a positive return ratio of 60.51%. Pension target FOFs rose 0.93% on average, with a positive return ratio of 99.50%. QDII funds fell 0.11% on average, with a positive return ratio of 58.16% [2][34]. - The top three sectors with the largest increase in positions of active equity funds last week were media, commerce and retail, and real estate; the top three sectors with the largest decrease in positions were electronics, non - ferrous metals, and pharmaceutical biology. As of February 27, 2026, the overall position of active equity funds was 77.23%, an increase of 0.81 pct from the previous period [2][40][42]. - Last week, the overall ETF market had a net capital outflow of 22.828 billion yuan. Stock - type ETFs had a relatively large net outflow of 36.286 billion yuan. The daily average trading volume of the overall ETF market reached 476.804 billion yuan, the daily average trading volume reached 168.72 billion shares, and the daily average turnover rate was 7.40%. The Hang Seng Technology, power grid equipment, securities, and Internet sectors had net capital inflows, with the Hang Seng Technology having a capital inflow close to 10 billion yuan. Broad - based indices such as the CSI 1000, CSI A500, CSI Small Cap 500, CSI 300, and SSE STAR 50 were the main varieties with capital outflows [3][46][49]. - Last week, 36 new funds were issued, an increase of 28 from the previous period; 5 new funds were established, a decrease of 59 from the previous period. New funds raised a total of 1.451 billion yuan, a decrease of 56.879 billion yuan from the previous period [4][54][59]. 3. Summary According to Relevant Catalogs 3.1 Market Review 3.1.1 Domestic Market Situation - From February 24 to February 27, 2026, all major equity market indices rose, with the CSI 500 rising 4.32%. Among the 31 Shenwan primary industries, 25 industries rose, and 6 industries fell. The top five gainers were steel, non - ferrous metals, chemicals, environmental protection, and coal; the top five decliners were media, commercial trade, food and beverages, non - bank finance, and banks. In the bond market, the ChinaBond Composite Full - Price Index fell 0.14%, and the total full - price indices of ChinaBond Treasury bonds, financial bonds, and credit bonds fell between 0.01% and 0.31%. The CSI Convertible Bond Index fell 0.23%. In the commodity market, the Nanhua Commodity Index rose 3.56% [12]. 3.1.2 European, American, and Asia - Pacific Market Situation - Last week, most major indices in European, American, and Asia - Pacific markets rose. In the US stock market, the S&P 500 rose 0.21%, the Dow Jones Industrial Average rose 0.34%, and the Nasdaq rose 0.18%. In the European market, the French CAC40 rose 0.98%, and the German DAX rose 1.17%. In the Asia - Pacific market, the Hang Seng Index fell 1.67%, and the Nikkei 225 rose 3.56% [20]. 3.1.3 Market Valuation Situation - Last week, the valuation quantiles of most major market indices rose. In terms of the historical quantile of price - to - earnings ratio, the CSI All - Share Index had the largest increase of 8.6 pct. In terms of the historical quantile of price - to - book ratio, the CSI 1000 had the largest increase of 5.4 pct. Among industries, the top five industries with the highest historical quantiles of price - to - earnings ratio of the Shenwan primary index were real estate, electronics, building materials, comprehensive, and chemicals. The price - to - earnings ratio quantile of real estate remained at a high level, and that of electronics reached 96.9%. The bottom five industries with the lowest historical quantiles of price - to - earnings ratio were non - bank finance, agriculture, forestry, animal husbandry and fishery, food and beverages, beauty care, and pharmaceutical biology. The valuation of the non - bank finance industry was close to its historical low since 2013 [23]. 3.2 Active Public - Offering Fund Situation - Market hotspots: The CSRC issued the "Administrative Measures for the Supervision of Information Disclosure of Private Investment Funds", which takes effect on September 1, 2026. The Shanghai Stock Exchange and China Securities Index Co., Ltd. announced the adjustment of constituent stocks of key indices such as the STAR 50, to be implemented after the close on March 13, 2026 [31][33]. - Fund performance: Quantitative funds had the largest increase, with an average increase of 2.22% and a positive return ratio of 92.26%. Fixed - income + funds rose 0.30% on average, with a positive return ratio of 73.12%. Pure - bond funds rose 0.01% on average, with a positive return ratio of 60.51%. Pension target FOFs rose 0.93% on average, with a positive return ratio of 99.50%. QDII funds fell 0.11% on average, with a positive return ratio of 58.16% [34]. - The top three sectors with the largest increase in positions of active equity funds last week were media, commerce and retail, and real estate; the top three sectors with the largest decrease in positions were electronics, non - ferrous metals, and pharmaceutical biology. As of February 27, 2026, the overall position of active equity funds was 77.23%, an increase of 0.81 pct from the previous period [40][42]. 3.3 ETF Fund Situation - Last week, the overall ETF market had a net capital outflow of 22.828 billion yuan. Stock - type ETFs had a relatively large net outflow of 36.286 billion yuan. The daily average trading volume of the overall ETF market reached 476.804 billion yuan, the daily average trading volume reached 168.72 billion shares, and the daily average turnover rate was 7.40%. The Hang Seng Technology, power grid equipment, securities, and Internet sectors had net capital inflows, with the Hang Seng Technology having a capital inflow close to 10 billion yuan. Broad - based indices such as the CSI 1000, CSI A500, CSI Small Cap 500, CSI 300, and SSE STAR 50 were the main varieties with capital outflows [3][46][49]. 3.4 Fund Issuance Statistics - Last week, 36 new funds were issued, an increase of 28 from the previous period, including 15 active equity - biased funds and 10 passive index funds. The 10 passive index funds were all stock - type, mainly tracking indices such as the CSI Battery Theme, Hang Seng Biotechnology, ChiNext 50, and agriculture, forestry, animal husbandry and fishery. Currently, the issuance share of active equity funds is still at a historical low, but there has been an obvious upward trend since this year. - Five new funds were established last week, a decrease of 59 from the previous period. New funds raised a total of 1.451 billion yuan, a decrease of 56.879 billion yuan from the previous period. The E Fund CSI Battery Theme ETF managed by Li Xu had the largest raised scale of about 859 million yuan [54][59].

2026 年 3 月 A 股重点指数调样公告解读 1 、 《 缠 论 技 术 分 析 框 架 解 析 》 2026-02-12 2、《2026 年 3 月 A 股重点指数调样 预测及投资机会解读》2026-02-07 3、《主动权益基金 2025 四季度持仓 解析》2026-01-23 证券研究报告/金融工程专题报告 2026 年 03 月 01 日 分析师：何青青 执业证书编号：S0740525070007 Email：heqq@zts.com.cn 分析师：吴先兴 执业证书编号：S0740525110003 Email：wuxx02@zts.com.cn 报告摘要 3 月指数样本股调整在即，把握事件窗口期 2026 年 2 月 27 日，中证指数公司公布了 3 月 16 日即将生效的指数定期调样名单。 本次定期调样涉及的重点指数为科创 50、科创创业 50、科创 100、红利低波 100、 北证 50。我们定量测算了相关个股的影响，供投资者参考。 基于最新调样公告的个股冲击测算 相关报告 基于中证指数公司公布的拟调样名单，结合近期交易数据及指数权重规则，我们汇总 估算了 5 个指数调样对个股的综合冲击。其 ...

近日，君实生物发布公告称，2025年度主要财务数据初步核算显示，公司营业总收入为24.98亿元，同 比增长28.23%。报告期内，归母净利润约亏损8.74亿元，较上年同期亏损12.81亿元有所改善。 公告中提到，公司核心产品特瑞普利单抗注射液（拓益®）在国内市场销售收入同比大幅增长约 37.72%。截至公告披露日，拓益®已在中国内地获批上市的适应症全部纳入国家医保目录，并在全球多 个国家和地区获得上市批准。公司实施股票期权激励计划，虽然股份支付费用增加，但通过加强费用管 控和资源聚焦，归母净亏损金额显著缩窄。 (编辑：杨燕 林辰)关键字： 医疗 （君实生物公告） ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以上海君实生物 医药科技股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：人民币万元 ■ 报告期内，公司核心产品特瑞普利单抗注射液（商品名：拓益?）于国内市场销售收入同比大幅增长约 37.72%。截至本公告披露日，拓益?已在中国内地获批上市的12项适应症全部纳入国家医保目录，是目 录中唯一用于肾癌、三阴性乳腺癌和黑色素瘤治疗的抗PD-1单抗药物。 公司亦持续拓展全球商业化网络，截至本公告披露日，特瑞普利单抗已在中国内地、中国香港、美国、 欧盟、印度、英国、澳大利亚和新加坡等40多个国家和地区获批上市，并在全球多个国家和地区接受上 市审评。 随着已获批产品和适应症纳入国家医保目录后可及性的提高，未来更多产品和适应症的陆续获批上市， 以及持续不断的全球市场商业化拓展，公司的商业化竞争力将获得持续提升。 2025年度，公司持续落实 ...